Latest / Finance TL;DR Daily / Fed Minutes Reveal Rate-Hike Split as Warsh Skips His First Dot Plot
Transcript
- Fed Minutes Reveal Rate-Hike Split as Warsh Skips His First Dot Plot 2026-07-09 Welcome to Finance TL;DR Daily, the podcast where we break down the biggest stories in finance. It's Thursday, July ninth. Today's big one: the Federal Reserve just showed its hand, and it turns out the people running the world's most important central bank can't agree on which way interest rates should even go next. Here's what's moving today. Start with the Fed. Minutes from the June sixteenth and seventeenth meeting dropped, and they cover the very first meeting under newly appointed Chair Kevin Warsh. The committee did vote unanimously to hold the benchmark rate at three-and-a-half to three-and-three-quarters percent, so no surprise there. But look past the vote and the minutes tell a messier story. Of the eighteen participants who submitted projections, eight wanted to hold rates steady, while nine actually expected at least one rate hike before the year is out. That's not a dovish committee leaning toward cuts — that's a committee leaning, however narrowly, toward tightening. The minutes put it plainly, saying, quote, "participants generally assessed that information received over the inter-meeting period suggested that upside risks to price stability remained elevated," end quote. In other words, inflation worry is winning the internal argument right now. Here's the twist that makes this even more notable: Chair Warsh didn't submit his own rate forecast at all. That makes him the first Fed chief to skip the so-called dot-plot estimate since that chart was introduced back in 2012. For markets, the takeaway is straightforward — any hope for near-term rate cuts just took a real hit, and the door to another hike this year is open wider than investors expected. When the people setting the price of money can't agree, the safest assumption for now is that money stays expensive for longer. That backdrop of a cautious Fed lines up almost too neatly with our next story, because it's the everyday American household that's already feeling squeezed — and PepsiCo just handed us the receipts. The snack and beverage giant reported second-quarter results on July ninth, and it's a split picture. Core earnings came in at two dollars and twenty cents a share, just a penny short of Wall Street's two-twenty-one estimate. Revenue actually beat expectations, up six-point-four percent year over year to twenty-four-point-eight billion dollars, ahead of the twenty-three-point-nine-five billion analysts had modeled — but that strength came from overseas markets, not home turf. In North America, the cracks show. Food organic sales fell two percent, and beverage organic volumes dropped four percent. CEO Ramon Laguarta said it directly: quote, "results were tempered in the quarter as U.S. food and beverage category performance moderated with consumer budgets tightening due to rising inflationary pressures," end quote. Why does a chips-and-soda earnings miss matter beyond PepsiCo shareholders? Because Pepsi sells small, cheap, everyday items — the kind of purchase that's usually the last thing people cut. When volumes on chips and soda start shrinking in the U.S. specifically, that's a pretty loud signal that middle- and lower-income households are actively trimming non-essential spending. Combine that with a Fed that's not in a hurry to cut rates, and you've got a consumer under real pressure with limited relief coming from borrowing costs any time soon. Moving to the drug industry now, because AstraZeneca just had one of its roughest days in years. Shares plunged as much as nine-and-a-half percent on July ninth, erasing roughly nineteen billion pounds in market value in a single session. The cause: the company's experimental heart drug Wainua, developed alongside Ionis Pharmaceuticals, failed its late-stage Phase III trial, known as CARDIO-TTRansform. Adding Wainua to standard treatment in this 1,432-patient study did not produce a statistically significant improvement in reducing cardiovascular death or recurrent clinical events versus a placebo. That's a real blow, because analysts had pegged this drug's peak annual sales potential at somewhere between two and three-point-three billion dollars. AstraZeneca's Sharon Barr, who leads biopharmaceuticals research and development, tried to put a constructive spin on it, saying, quote, "although the trial did not meet its primary objective, we believe the results support greater scientific understanding of treatment approaches," end quote. But make no mistake — clinical trial failures of this size, at this stage, are rare for a company of AstraZeneca's scale, and this one lands right as the company is trying to convince investors it can hit an ambitious eighty-billion-dollar annual revenue target by 2030. Losing a multi-billion-dollar pipeline bet doesn't kill that goal outright, but it does raise the bar for everything else in the pipeline to perform. Last stop today is China, where the economic data is sending two different messages at once. Consumer prices rose just one percent year over year in June, actually slowing from May's one-point-two percent gain and missing the one-point-one percent economists expected. Weak demand at home, in other words. But flip to the factory floor and it's the opposite story — producer prices climbed four-point-one percent year over year, up from three-point-nine percent in May, and that's the fastest pace since July of 2022. Capital Economics analysts noted that the softness was led by lower energy inflation, but pointed out that even core inflation edged down too, calling it evidence of, quote, "wider disinflationary forces still present in the Chinese economy," end quote. Why should anyone outside China care? Because this combination — weak consumer spending paired with rising costs to actually manufacture goods — squeezes profit margins for exporters, and those higher factory-gate costs have a way of eventually showing up in the price tags of goods shipped worldwide. It's a reminder that global supply chains are still absorbing shocks even as domestic demand in the world's second-largest economy stays soft. So to sum up the day: a divided Fed just made near-term rate cuts look far less likely, American consumers are visibly pulling back on the small stuff, a rare pharma trial failure cost AstraZeneca billions in value, and China's economy is sending mixed signals that could ripple through global pricing. This has been Finance TL;DR Daily. We'll see you tomorrow.